Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - AUXILIUM PHARMACEUTICALS INC | a12-16035_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 9, 2012
Auxilium Pharmaceuticals, Inc.
(Exact Name of Registrant Specified in Charter)
|
Delaware |
|
000-50855 |
|
23-3016883 |
|
(State or Other |
|
(Commission File |
|
(I.R.S. Employer |
|
Jurisdiction of |
|
Number) |
|
Identification No.) |
|
Incorporation) |
|
|
|
|
|
40 Valley Stream Parkway |
|
|
|
Malvern, PA |
|
19355 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (484) 321-5900
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On July 9, 2012, Auxilium Pharmaceuticals, Inc. (“Auxilium”) and Actelion Pharmaceuticals Canada Inc. issued a joint press release announcing that Auxilium was granted a Notice of Compliance (approval) by Health Canada for XIAFLEX® (collagenase clostridium histolyticum or CCH), a novel, first-in-class biologic for the treatment of Dupuytren’s contracture in adults with a palpable cord in Canada.
The full text of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Joint Press Release, dated July 9, 2012, issued by Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Canada Inc.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AUXILIUM PHARMACEUTICALS, INC. | |
|
|
| |
|
|
| |
|
Date: July 9, 2012 |
By: |
/s/ James E. Fickenscher |
|
|
|
|
|
|
|
James E. Fickenscher |
|
|
|
Chief Financial Officer |